CD20 drugs for Chronic Lymphocytic Leukemia
4 tracked CD20 drugs in the Chronic Lymphocytic Leukemia race. The class explanation lives on the CD20 page; the full indication pipeline across every mechanism is on the Chronic Lymphocytic Leukemia page.
4 approved / phase 4
Head-to-head evidence: Obinutuzumab vs PF-05280586 · Obinutuzumab vs Rituximab · Obinutuzumab vs Rituximab-abbs (Truxima)